Growth inhibitory activity of Ankaferd hemostat on primary melanoma cells and cell lines

TÜRK TÜRK S., Malkan Ü. Y., Ghasemi M., Hocaoglu H., Mutlu D., Gunes G., ...Daha Fazla

SAGE OPEN MEDICINE, cilt.5, 2017 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 5
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1177/2050312116689519
  • Dergi Adı: SAGE OPEN MEDICINE
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
  • Anahtar Kelimeler: Ankaferd hemostat, anticancer, melanoma, MEDICINAL-PLANT EXTRACT, CONTROLLED CLINICAL-TRIAL, PARTIAL NEPHRECTOMY MODEL, RENAL TUBULAR APOPTOSIS, BLOOD STOPPER, IN-VITRO, PULPOTOMY, AGENTS, ABS
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Objective: Ankaferd hemostat is the first topical hemostatic agent about the red blood cell-fibrinogen relations tested in the clinical trials. Ankaferd hemostat consists of standardized plant extracts including Alpinia) officinarum, Glycyrrhiza glabra, Thymus vulgaris, Urtica dioica, and Vitis vinifera. The aim of this study was to determine the effect of Ankaferd hemostat on viability of melanoma cell lines.